Abstract
Cancer is a fast-growing disease responsible for many deaths worldwide. Due to its aggressive and forever-changing nature, it is imperative to find alternative anti-cancer agents that could possibly treat this disease. Silver(I) phosphine complexes were synthesized by reaction of AgNO3, AgCl, and AgBr with cyclohexyldiphenylphosphine to produce 1:1, 1:2, or 1:3 molar ratios of new silver complexes with the formulas [Ag(PPh2Cy)NO3] (1), [Ag(PPh2Cy)2NO3] (2), [Ag(PPh2Cy)3NO3] (3), [Ag(PPh2Cy)2Cl] (4), [Ag(PPh2Cy)3Cl] (5), and [Ag(PPh2Cy)3Br] (6), respectively. The complexes were characterized by elemental analyses, FT-IR and 1H, 13C, 31P NMR spectroscopic techniques. The crystal structures of 5 (CCDC 1480482) and 6 (CCDC 2183297) were determined by single-crystal X-ray diffractometry. All six complexes were evaluated as potential anti-cancer agents in four different human malignant (SNO, MCF-7, A375, and A549) cell lines and one human non-malignant (HEK293) cell line. Overall, these complexes were significantly cytotoxic to both cancerous and non-cancerous cells and are therefore not considered suitable anti-cancer agents in their current form.
| Original language | English |
|---|---|
| Pages (from-to) | 45-60 |
| Number of pages | 16 |
| Journal | Journal of Coordination Chemistry |
| Volume | 76 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2023 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Silver(I) complexes
- anti-cancer activity
- crystal structure
- cyclohexyldiphenylphosphine
- cytotoxicity
ASJC Scopus subject areas
- Physical and Theoretical Chemistry
- Materials Chemistry
Fingerprint
Dive into the research topics of 'Synthesis, crystal structure and spectral studies of silver(I) cyclohexyldiphenylphosphine complexes: towards the biological evaluation on malignant and non-malignant cells'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver